The clinical trials of the immune checkpoint inhibitors as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have promising results with other cancer types, whereas they have been unsuccessful in PDAC6,8. This evidence concerns the gene PDCD1 and cancer.